huberman glp-1 The Science of Hunger & Medications to Combat Obesity | Dr. Zachary Knight - Lab Premium Opinion | GLP-1 Experimentation Is

Carter S, Clifton PM, Keogh JB (2019) The effect of intermittent compared with continuous energy restriction on glycaemic control in patients with type 2 diabetes: 24-month follow-up of a randomised noninferiority trial

In North Carolina, the state employee health plan initiated coverage of GLP-1s for weight loss purposes in 2015

Ipamorelin benefits include favorable side effect profile

While these mechanisms contribute to weight loss success, they can also result in gastrointestinal side effects, including nausea, constipation, and, importantly, diarrhea

In addition, a composite endpoint comprised of participants who achieved an HbA1C level 6.5% and weight loss of at least 10%, was assessed

Some patients benefit from repeating labs (fasting glucose, lipid panel) 4-6 weeks after full discontinuation to confirm metabolic stability